Comorbidities Schizophrenia-Addiction to Cannabis and Tobacco in Madagascar in 2022

R.F. Randrianarivo, H.H. Ratobimanankasina, B.O.N. Rakotoarinelina, N. Mohamed, B.H. Rajaonarison, A. Raharivelo

Abstract


The use of psychoactive substances is frequent in schizophrenic patients. The main objective was to determine the prevalence of schizophrenia-addiction comorbidity and to characterize its evolution.This is an observational, cross-sectional, descriptive and bicentric study carried out in the Psychiatry Department of the Professor Zafisaona Gabriel University Hospital Center and at the Toby Peniela in Antanimasaja over a period of 4 months from February to May 2022.All schizophrenics meeting DSM-V criteria were included. It was collected 60 patients. The average age was 30.60 years, a sex ratio of 2.15; Joblessness was found in 45%. The prevalence of active drug taking was 91.66%, including cannabis in 60% and tobacco in 40%. Non-deficient schizophrenia predominated in 53.33% of cases and 66.67% of them were cannabis users and 61.11% of these cannabis patients had grown up in a “non-biparental” situation. The age of onset of drug intake was 17.5 years and the time between drug intake and psychiatric disorders was 3.25 years. The begining of the disease for addicted patients was at 22.52 years and for those non-addicted one at 30.6 years. Cannabis addiction was found in 51.61%.Strengthening the fight against drug addiction, increasing sensitization of psychiatric pathologies and supporting single-parent families could reduce the prevalence of drug addiction and improve their care.

Keywords


Addiction, cannabis, misuse, schizophrenia, troubles

Full Text:

PDF

References


Azzeddine R. Comorbidité schizophrénie-addiction au cannabis [Thèse]. Médecine : Oran;2017.235p.

Hamilton I. Cannabis, psychosis and schizophrenia: unravelling a complex interaction. Addiction 2017;112:1653‑7.

Lévy-Chavagnat D. Cannabis et schizophrénie : des liens reconnus. Actualités Pharmaceutiques 2010;49:30‑4.

Dervaux A, Laqueille X. Tabac et schizophrénie : aspects épidémiologiques et cliniques. LEncéphale 2008;34:299‑305.

Coulibaly SP, Dolo H, Notue CAM, Sangaré M, Mounkoro PP, Aboubacar A, et al. Épidémiologie hospitalière des troubles psychiatriques au Mali. 2022;41:160.

Bakohariliva HA, Rafehivola IH, Raobelle EN, Raharivelo A, Rajaonarison BH. Etat des lieux des soins de premier recours des malades mentaux à Antananarivo : étude rétrospective. Pan African Medical Journal 2018;29:1‑6.

Ndambo Mbuyi R. Fréquence et prise en charge de la schizophrénie à Lubumbashi [Thèse]. Médecine : Lubumbashi;2015.63p.

Rouillon F. Epidémiologie des troubles psychiatriques. Ann Méd psychol 2007;166:63—70.

Charlson FJ, Ferrari AJ, Santomauro DF, Diminic S, Stockings E, Scott JG, et al. Global Epidemiology and Burden of Schizophrenia: Findings From the Global Burden of Disease Study 2016. Schizophr Bull 2018;44:1195‑203.

Ousmane D. Approche épidémiologique de la Schizophrénie au service de psychiatrie du CHU du Point G [Thèse]. Médecine : Bamako;2010.76p.

Bouri S, Hanane H, Idrissi KEA, Berraho MA, Abdellaoui A, Badiaa L, et al. Determining factors for Cannabis use among Moroccans Schizophrenic Patients: A cross sectional study. Avicenna J Phytomed 2020;10:89‑100.

Delignère AL, Archambault G, Chalvin F, Perquier F, Lejoyeux M. Schizophrénie et addictions : Étude exploratoire chez 106 patients suivis en consultation. Annales Médico-psychologiques, revue psychiatrique 2020;178:226‑32.

Tanteliniaina LMR. Urgences psychiatriques dans le district de Mahajanga II : Etude épidémiologique et problèmes de prise en charge [Thèse]. Médecine : Mahajanga;2009.86p.

Coffey C, Carlin JB, Degenhardt L, Lynskey M, Sanci L, Patton GC. Cannabis dependence in young adults : an Australian population study. Addiction 2022;97(2):187-94.

Tekin Uludağ Y, Güleç G. Prevalence of Substance Use in Patients Diagnosed with Schizophrenia. Noro Psikiyatr Ars 2016;53:4‑11.

Frank N. La clinique de la schizophrénie. Paris : Elsevier Masson - Psychiatrie 2013;10(1):1-16 [Article 37-282-A-20].

Andriantseheno L, Andrianasy T, Andriambao D. Les troubles psychiatriques à Madagascar: étude clinique de 376 cas répertoriés à Mahajanga. Bull Soc Pathol Exot 2004;97:122‑6.

Thomas P, Amad A, Fovet T. Schizophrénie et addictions : les liaisons dangereuses. LEncéphale 2016;42:S18‑22.

Ruddy R, Milnes D. Art therapy for schizophrenia or schizophrenia‐like illnesses. Cochrane Database of Systematic Reviews [Internet] 2005; Disponible sur https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003728.pub2/full

Dalack GW, Becks L, Hill E. Nicotine withdrawal and psychiatric symptoms in cigarette smokers with schizophrenia. Neuropsychopharmacology 1999;21:195- 202.

De Leon J, Tracy J, McCann E. Schizophrenia and tobacco smoking: a replication study in another US psychiatric hospital. Schizophr Res 2002;56(1-2):55-65.

Seklaoui S. Approches épidémiologiques, données sociologiques et abords thérapeutiques de la Schizophrénie au service de psychiatrie du CHU NEDIR Mohammed de Tizi-Ouzou et à lEHS de Oued Aissi [Thèse]. Médecine : Tizi Ouzou;2021.143p.




DOI: http://dx.doi.org/10.52155/ijpsat.v37.1.5027

Refbacks

  • There are currently no refbacks.


Copyright (c) 2023 RANDRIANARIVO Raphaël Fidelis

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.